BRIEF published on 09/18/2024 at 07:05, 1 year 7 months ago Relief Therapeutics achève la phase clinique de l'étude RLF-OD032 Étude Clinique RLF-OD032 Biodisponibilité Phénylcétonurie Dichlorhydrate De Saproptérine
BRIEF published on 09/18/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 7 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 8 months ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 1 year 8 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 8 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 8 months ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 1 year 8 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 8 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 9 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
Published on 05/08/2026 at 01:50, 7 hours 18 minutes ago Apex Critical Metals Announces Grant of Stock Options and RSUs
Published on 05/08/2026 at 00:45, 8 hours 23 minutes ago Route1 Announces First Quarter 2026 Financial Results Notification
Published on 05/08/2026 at 00:00, 9 hours 8 minutes ago Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 9 hours 38 minutes ago Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 9 hours 53 minutes ago BULGOLD Adopts Semi-Annual Financial Reporting
Published on 05/08/2026 at 08:30, 37 minutes ago Original-Research: Warimpex Finanz- und Beteiligungs-AG (von East Value Research GmbH ):
Published on 05/08/2026 at 08:30, 38 minutes ago ONATi/Vini strengthens customer protection: cyan AG becomes new cybersecurity partner in French Polynesia
Published on 05/08/2026 at 08:02, 1 hour 6 minutes ago Commerzbank delivers strong first quarter and targets Net RoTE of 21% by 2030
Published on 05/08/2026 at 08:00, 1 hour 7 minutes ago LIBERO to attend the World Football Summit in Madrid
Published on 05/08/2026 at 07:58, 1 hour 10 minutes ago Commerzbank delivers strong first quarter and targets Net RoTE of 21% by 2030
Published on 05/07/2026 at 19:15, 13 hours 53 minutes ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 13 hours 53 minutes ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 14 hours 2 minutes ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 14 hours 2 minutes ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 14 hours 8 minutes ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
